Abstract: An accumulating body of evidence indicates that an increased endothelin-1 level is related to endothelial dysfunction in cardiovascular diseases. In this study, we tested whether prolonged treatment of aortas with endothelin-1 induces endothelial dysfunction. When isolated aortas from control rats were cultured with endothelin-1, at levels above the plasma concentration, the acetylcholine-induced endothelium-dependent relaxation was significantly decreased (as compared with endothelin-1-nontreatment). This endothelin-1-induced endothelial dysfunction was more marked in aortas obtained from rats with streptozotocininduced diabetes than in those from the controls. The endothelin-1-induced attenuation was very strongly suppressed by co-incubation with J-104132, endothelin receptor A/B antagonist, or polyethyleneglycolated superoxide dismutase, a cell-permeant superoxide anion scavenger or LY294002, phosphoinositide 3-kinase inhibitor. These results indicate that endothelin-1 can induce endothelial dysfunction, and that this may be related to superoxide generation and to PI3-kinase activity.
T he powerful vasoconstrictor endothelin-1 (ET-1), a 21-amino acid peptide secreted from endothelial cells, is thought to play a pathological role in a number of vascular diseases. 1, 2 Indeed, elevated plasma levels of ET-1 have been found in a variety of pathophysiological conditions, including atherosclerosis, hypertension and diabetes. [1] [2] [3] [4] [5] There is an accumulating body of evidence to show that the relaxation responses induced in aortic strips by endothelium-dependent agents are weaker in rats with streptozotocin (STZ)-induced diabetes than in non-diabetic control rats. [6] [7] [8] [9] [10] Thus, endothelial dysfunction is likely to play a key role in the pathogenesis of diabetic vasculopathy. 10 Oxygen-derived free radicals are involved in mediating the effects of vascular injury in various disease states, such as diabetes; 11 for example, superoxide dismutase (SOD) activity is reduced in aortas from diabetic rats. Increased production of superoxide anion (O 2 -) may cause an impairment of endothelium-dependent relaxation. [7] [8] [9] The increased plasma ET-1 level in diabetic rats may be a cause of the endothelial dysfunction seen in diabetes. If this is indeed the case, prolonged treatment of normal blood vessels with ET-1 should impair endothelial function. However, little is known about the effect of the vasoactive and potentially proatherogenic agent ET-1 on O 2 -generation and endothelial function. The aim of this study was to investigate the link between ET-1 and the endothelial dysfunction in control and diabetic rats using an organculture system.
MATERIALS AND METHODS

Drugs
Streptozotocin, nitro blue tetrazolium (NBT), diethylentriaminepentaacetic acid, (-)noradrenaline hydrochloride (NA), polyethylene-glycolated superoxide dismutase (PEG-SOD), LY294002 and sodium nitroprusside (SNP) were all purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.). Acetylcholine chloride (ACh) was from Daiich Pharmaceutical Co. Ltd. (Tokyo, Japan). J-104132 {(+)-(5S,6R,7R)-2-butyl-7-[2-((2S)-2-carboxypropyl)-4-m e t h o x y p h e ny l ] -5 -( 3 , 4 -m e t h y l e n e d i o x y p h e ny l ) cycloperteno[1,2-b]pyridine-6-carboxylic acid} was a gift from Banyu Co. Ltd. (Tsukuba, Japan). All drugs were dissolved in distilled water. All concentrations are expressed as the final molar concentration of the base in the organ bath. adopted by Hoshi University (which is accredited by the Ministry of Education, Science, Sports and Culture, Japan).
Organ-culture Procedure and Measurement of Isometric Force
Rats were anaesthetized with diethyl ether and killed by decapitation 11 weeks after treatment with STZ or buffer. The aorta was cleaned of loosely adhering fat and connective tissue, then cut into transverse rings. These were placed in 5 mL of serum-free Leibovitz's L-15 medium supplemented with 1% penicillin-streptomycin containing 3 nM ET-1 or vehicle and maintained at 37°C for 16-18 hours. Some rings were placed in a similar solution containing not only ET-1 (3 nM) but also J-104132 (5 nM), PEG-SOD (41 U/ml) or LY294002 (10 µM), and were again maintained at 37°C for 16-18 hours. After incubation, each aorta (cut into helical strips) was placed in a bath containing 10 mL modified Krebs-Henseleit solution, consisting of 118.0 mM NaCl, 4.7 mM KCl, 25.0 mM NaHCO 3 , 1.8 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , and 11.0 mM dextrose, bubbled with 95% O 2 plus 5% CO 2 , and kept at 37°C. One end of each strip was connected to a tissue holder and the other to a force-displacement transducer, as previously described. 8, 9, 12, 13 For the relaxation studies, the aortic strips were precontracted with an equieffective concentration of NA (5 × 10 -8~3 × 10 -7 mol/L). When the NA-induced contraction had reached a plateau level, ACh (10
-5 mol/L) was added in a cumulative manner.
Quantification of Superoxide Anion by Measurement of the Amount of Reduced NBT
Aortic rings were incubated with NBT to allow the O 2 -generated by the tissue to reduce the NBT to blue formazan. The details of this assay have been published previously.
14 Briefly, aortas obtained from control rats were cut into transverse rings 10 mm in length and these were placed in 5 mL of serum-free Leibovitz's L-15 medium supplemented with 1% penicillin-streptomycin containing one of the following: vehicle, ET-1 (3 nM), ET-1 (3 nM) plus J-104132 (5 nM), or ET-1 (3 nM) plus LY294002 (10 µM). The rings were kept in these solutions for 16 hours at 37°C. This procedure was conducted using aortas from STZ-diabetic and age-matched control rats. The rings were then placed for 1.5 hours at 37°C in 5 mL buffer containing NBT (100 µM).
The NBT reduction was stopped by the addition of 0.5 N HCl (5 mL). After this incubation, the rings were minced and homogenized in a mixture of 0.1 N NaOH and 0.1% sodium dodecyl sulfate in water containing 40 mg/L diethylentriaminepentaacetic acid. The mixture was centrifuged at 20 000 g for 20 minutes and the resultant pellet resuspended in 1.5 mL of pyridine kept at 80°C for 1.5 hours to extract formazan. The mixture was then subjected to a second centrifugation at 10 000 g for 10 minutes. The absorbance of the formazan was determined spectrophotometrically at 540 nm. The amount of NBT reduced (= quantity of formazan) was calculated as follows: amount of NBT reduced = A·V/(T·Wt·ε·l), where A is the absorbance, V is the volume of pyridine, T is the time for which the rings were incubated with NBT, Wt is the blotted wet weight of the aortic rings, ε is the extinction coefficient (0.7 L/mmol per mm) and l is the length of the light path. The results are reported in pmol/min per mg Wt.
Statistical Analysis
Data are expressed as the means ± standard error of the mean (SEM). When appropriate, statistical differences were assessed using Dunnett's test for multiple comparisons after a one-way analysis of variance (ANOVA), a probability level of P < 0.05 being regarded as significant. Statistical comparisons between concentration-response curves were made by means of a two-way ANOVA, with Bonferroni's correction for multiple comparisons being performed post hoc (P < 0.05 again being considered significant).
RESULTS
As reported previously, 12, 13, 15 at the time of the experiment all STZ-induced diabetic rats exhibited hyperglycaemia and their body weights were significantly lower than those of the age-matched control rats (data not shown).
As shown in Figure 1 , when the NA (5 × 10 -8~3 × 10 -7 mol/L)-induced contraction had reached a plateau, ACh (10 -9~1 0 -5 mol/) induced a concentrationdependent relaxation in all groups, with the maximum response at 10 -5 mol/L. This relaxation was significantly weaker in vehicle-treated strips from STZ-rats than in those from control rats. Interestingly, aortic strips from agematched control rats treated with ET-1 (3 nM) for 16-18 hours showed significantly impaired ACh-induced relaxation. This ET-1-induced endothelial dysfunction was more marked in aortas obtained from STZ-rats than in those from control rats (Fig. 1A) . The endothelium-independent relaxation induced by SNP (10
-5 mol/L) did not differ significantly between the various groups (Fig. 1B) .
In order to investigate the possible mechanisms underlying the impaired ACh-induced relaxation seen in ET-1-treated control rats, we examined the ACh response following co-incubation with ET-1 and one of a number of drugs. As shown in Figure 2 , in aorta co-treated with ET-1 (3 nM) and J-104132 (endothelin receptor A/B antagonist; 5 nM), the ET-1-induced attenuation of the ACh-induced relaxation was completely prevented. Similarly, the ET-1-induced impairment of the ACh-induced relaxation was significantly attenuated in the presence of PEG-SOD (a cellpermeant superoxide anion scavenger; 41 U/mL) or LY294002 [phosphoinositide-3-kinase (PI3K) inhibitor; 10 µM]
In our experiments to assess superoxide generation from measurements of the amount of NBT reduced by O 2 -, the non-cultured O 2 -level was significantly greater in aortic rings from diabetic rats than in those from controls (Fig. 3) . In aortas obtained from control rats and then treated with ET-1 (3 nM), the O 2 -level was significantly higher than that in the corresponding vehicle-treated group. Co-incubation with J-104132 (5 nM) or LY294002 (10 µM) normalized the elevated O 2 -level, the differences from the value for the ET-1-treated group being significant at P < 0.01 and P < 0.001, respectively (Fig. 3) . Each data point represents the mean ± SEM for 6-12 experiments; the SEM is included only when it exceeds the dimension of the symbol used.
## P < 0.01, ### P < 0.001, ET-1-treated versus co-treated group. FIGURE 3. Quantification of superoxide-anion production by measurement of the amount of reduced nitro blue tetrazolium (NBT) in aortas from age-matched control or streptozotocin-diabetic rats (non-cultured) or in endothelin-1 (ET-1)-treated control aortas (cultured). In the culture study, each tissue was treated for 16 hours with ET-1 (3 nM) alone or with vehicle, or was simultaneously co-treated with ET-1 (3 nM) and either J-104132 (endothelin receptor A/B antagonist; 5 nM) or LY294002 (phosphoinositide-3-kinase inhibitor; 10 µM). Each data point represents the mean ± SEM for 3-6 experiments. *P < 0.05, diabetic versus control; ## P < 0.01, ET-1 treated versus Vehicle. † †P < 0.01, † † †P < 0.001, ET-1 treated versus co-treated group.
DISCUSSION
The major findings made in this study were that ET-1 stimulates O 2 -production and also induces an impairment of endothelium-dependent relaxation, via the PI3K pathway, in aortas from both diabetic and non-diabetic rats.
Convincing evidence indicates that the major enzymatic sources of vascular superoxide are nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase, xanthine oxidase, and uncoupled nitric oxide synthase. 16 Activation of NAD(P)H oxidase requires several steps 17 and the mechanisms by which angiotensin II (Ang II) stimulates this oxidase by has been well studied. 17 Essentially, activation of the angiotensin AT 1 receptor leads to phosphorylation of p47 phox . Crucial steps between these two events include activations of phospholipase D, protein kinase C and c-Src tyrosine kinase. Phosphorylation of p47 phox promotes its binding to membrane oxidase components (p22 phox , NOX). c-Src also transactivates the epidermal growth factor receptor, which leads to activation of PI3K and Rac-1. Subsequently translocation of Rac-1 to the membrane further activates NAD(P)H oxidase and sustains its function. 17 It was recently reported that ET-1 can activate PI3K in several cells 18, 19 and that ET-1 activates NAD(P)H oxidase and induces superoxide production in cultured endothelial and smooth muscle cells. 20, 21 Moreover, ET-1 was found to increase vascular superoxide via the endothelin-A (ET A )/ NAD(P)H oxidase pathway in a low-renin deoxycorticosterone acetate-salt hypertension model. 22, 23 We have previously reported that: (i) the plasma ET-1 concentration is increased in STZ-induced diabetic rats and that this increase may be the result of an overexpression of the mRNA for preproendothelin-1; 3, 5 (ii) the overproduction of ET-1 seen in STZ-induced diabetes is a result of hyperglycaemia, not of an increase in low density lipoprotein cholesterol or triglyceride; 4 (iii) the expression of the mRNA for the p22 phox NAD(P)H oxidase subunit is significantly increased in STZ-induced diabetic rats, an increase that is completely prevented by prolonged administration of J-104132. 12 This suggests that ET-1 is involved in the synthesis of superoxide anion and that this effect may impair endothelium-dependent relaxation in diabetes. If so, an increase in ET-1 might be expected to play an important role in the endothelial dysfunction seen in the diabetic state. In the present study, ET-1-treated aortas showed significantly impaired ACh-induced relaxation and this ET-1-induced endothelial dysfunction was more marked in aortas obtained from STZ-diabetic rats than in those from the controls. Moreover, the ET-1-induced endothelial dysfunction and superoxide generation were completely prevented by cotreatment either with J-104132 [an affinity for ET A is only threefold greater than that for endothelin-B (ET B ) receptor 24 ] or with LY294002. In view of all the above findings, we speculate that ET-1 stimulates superoxide production through the pathway for ET A -PI3K-NAD(P)H oxidase activation and that this underlies the endothelial dysfunction seen in ET-1-treated aortas.
In conclusion, we found that prolonged treatment with ET-1 impairs endothelial function in the aorta in non-diabetic rats and in rats with established STZ-induced diabetes. Our results suggest that this dysfunction may be related to superoxide generation and to PI3K activity. We believe that our findings should stimulate further interest in ET-1-induced superoxide generation as a potential therapeutic target in the continuing efforts to reduce diabetes-associated vascular disease.
